Cited by 7Nanoplatforms for cancer theranosticsNanoparticle-Based Drug DeliveryRadiation Therapy and Dosimetry

Multifunctional nanocomposites DDMplusAF inhibit the proliferation and enhance the radiotherapy of breast cancer cells via modulating tumor-promoting factors and metabolic reprogramming

Open access
Thabet, Noura M., Abdel-Rafei, Mohamed K., El-Sayyad, Gharieb S., Elkodous, Mohamed Abd, Shaaban, Adel, Du, Yi-Chun, Rashed, Laila Ahmed, Askar, Mostafa A.·2022·Cancer Nanotechnology

Abstract

Abstract Background Tumor-promoting factors (TPF) and metabolic reprogramming are hallmarks of cancer cell growth. This study is designed to combine the newly synthesized two nanocomposites DDM (HA-FA-2DG@DCA@MgO) and AF (HA-FA-Amygdaline@Fe2O3) with fractionated doses of radiotherapy (6 Gy-FDR; fractionated dose radiotherapy) to improve the efficiency of chemo-radiotherapy against breast cancer cell lines (BCCs; MCF-7 and MDA-MB-231). The physicochemical properties of each nanocomposite were confirmed using energy dispersive XRD, FTIR, HR-TEM, and SEM. The stability of DDMPlusAF was also examined, as well as its release and selective cellular uptake in response to acidic pH. A multiple-MTT assay was performed to evaluate the radiosensitivity of BCCs to DDMPlusAF at 3 Gy (single dose radiotherapy; SDR) and 6 Gy-FDR after 24, 48, and 72 h. Finally, the anti-cancer activity of DDMPlusAF with 6 Gy-FDR was investigated via assessing the cell cycle distribution and cell apoptosis by flow cytometry, the biochemical mediators (HIF-1α, TNF-α, IL-10, P53, PPAR-α, and PRMT-1), along with glycolytic pathway (glucose, HK, PDH, lactate, and ATP) as well as the signaling effectors (protein expression of AKT, AMPK, SIRT-1, TGF-β, PGC-1α, and gene expression of ERR-α) were determined in this study. Results The stability of DDMPlusAF was verified over 6 days without nanoparticle aggregation. DDMPlusAF release and selectivity data revealed that their release was amenable to the acidic pH of the cancer environment, and their selectivity was enhanced towards BCCs owing to CD44 and FR-α receptors-mediated uptake. After 24 h, DDMPlusAF boosted the BCC radiosensitivity to 6 Gy-FDR. Cell cycle arrest (G2/M and pre-G1), apoptosis induction, modulation of TPF mediators and signaling effectors, and suppression of aerobic glycolysis, all confirmed DDMPlusAF + 6 Gy’s anti-cancer activity. Conclusions It could be concluded that DDMPlusAF exerted a selective cancer radiosensitizing efficacy with targeted properties for TPF and metabolic reprogramming in BCCs therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12645-022-00122-1

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Thabet, N. M., Abdel-Rafei, M. K., El-Sayyad, G. S., Elkodous, M. A., Shaaban, A., Du, Y.-C., Rashed, L. A., & Askar, M. A.
Affiliations
  • Egyptian Atomic Energy Authority (EG)
  • Toyohashi University of Technology (JP)
  • Medical Device Innovation Center (TW)
  • Cairo University (EG)
Corresponding author
  • Thabet, Noura M.
  • Du, Yi-Chun
Venue
Cancer Nanotechnology
Published
2022-05-28
Volume
13
Issue
1
ISSN
  • 1868-6958 (ISSN-L)
  • 1868-6966
OpenAlex
W4281699922
Cited by
7
References
79
Citations by year
2026: 1 · 2024: 2 · 2023: 4
FWCI
0.44
Type
journal article
Language
en
Open access
Locations
  • Cancer Nanotechnology (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
the Ministry of Science and Technology, Taiwan (MOST 108-2221-E-218-005-MY3 and 110-2221-E-006-087-MY3)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Radiation Therapy and Dosimetry
Keywords
breast cancer, nanocomposites, chemoradiotherapy, fractionated radiotherapy, metabolic reprogramming, aerobic glycolysis, 2-deoxyglucose, dichloroacetate, iron oxide nanoparticles, magnesium oxide nanoparticles, hyaluronic acid, folic acid, pH-responsive drug release, radiosensitization, apoptosis, cell cycle arrest, HIF-1α, PPARα, AMPK signaling, CD44, folate receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review